Inadequate nutrient intake, a survival benchmark in cancer cells, leads to oxidative stress (OS) disrupting homeostasis, activating signaling, and altering metabolism. As reactive oxygen species (ROS) increase, oxidative stressors activate mechanisms allowing cancer cells to adapt and survive. Our data suggests that nutrient‐deprived cancer cells tolerate OS. Moreover, a quiescent phenotype along with nuclear factor‐kappaB (NF‐κB) signaling may synergistically protect tumor cells from OS induced by nutrient deprivation. In DU145 prostate cancer cell line, we observed that serum‐deprived cells maintained viability after exposure to H2O2 and transitioned to a quiescent phenotype via up‐regulated quiescent markers. Additionally, we transiently silenced NF‐κB (RelA/p65) via siRNA, and demonstrated the percentage of total apoptosis in DU145 cells significantly increased in serum‐deprived cells exposed to H2O2. Furthermore, we observed that inhibition of quiescence significantly reduced NF‐κB‐mediated cell survival in response to OS using two quiescence inhibitors targeting Mirk/Dyrk1b kinase (quiescence inducer), AZ191 and NCGC00185981‐05/ML195; concomitantly, a distinct NF‐κB nuclear localization was not observed. It is unclear how prostate cancer cells adapt and survive oxidative stress; however, we hypothesize nutrient deprivation primes cancer cells for OS cell survival, concurrent with a transition to a quiescent phenotype and NF‐κB signaling. Support or Funding Information These studies were supported by the NIH/NIGMS/RISE #5R25GM060414‐15 and NIH/NIHMD/RCMI #5G12MD007590.
Heterodimerization of G protein-coupled receptor exemplifies that GPCRS can change intracellular signaling that would result from each individual receptor. Yet, how heterodimers affect receptor pharmacology remains unknown. We've demonstrated that agonist-bound C-X-C Chemokine Receptor 4 (CXCR4) and Cannabinoid Receptor 2 (CB2) formed a non-functional heterodimer on the membrane of cancer cells, inhibiting their migratory potential in vitro. The impact on the signaling entities responsible for reduced migration upon heterodimerization remain elusive, and therefore, we investigated whether the physical association of CXCR4 and CB2 resulted in decreased signaling from the CXCR4-mediated Gα13/RhoA signaling axis, which leads to phenotypic changes involved in migration. To depict receptor specificity in the role of heterodimer formation on downstream signaling events, we used human siRNA against CXCR4 prior to assaying for Gα13/RhoA immune-complexes to demonstrate that heterodimerization of CXCR4/CB2 decreased RhoA activation with the same potency as genomic knockdown of CXCR4 (PC3). To demonstrate that agonist-induced CXCR4/CB2 heterodimerization attenuated RhoA-dependent cell migration, we immunoblotted for PRG protein expression to determine the heterodimer reduced expression of PDZ-RhoGEF (PRG) which is required for RhoA-dependent cell migration and immunoblotted for LKB1, an establish regulator of RhoA-dependent cell polarity. Finally, to characterize the reduction of RhoA-mediated signaling, we performed both wound healing and transwell migration assays in PC3 cells. In PC3 cells transfected with CXCR4-siRNA, we observed a significant reduction in Gα13/RhoA immune-complexes, which was analogous to samples where CXCR4 and CB2 heterodimerized, suggesting that the physical heterodimer is a viable strategy for antagonizing CXCR4. Immunoblotting techniques revealed that the heterodimer decreased PRG protein expression levels in PC3 cells, compared to cells where CXCR4 signaling was active. The reduction in RhoA signaling upon heterodimerization is directly linked to the propensity of cells to migrate as we saw reduced transformation, reduced wound healing, and reduced migration compared to cells where CXCR4 signaling was active. Our results indicate mechanistic insight into our previous observation that a physical heterodimer reduces cell migration via antagonism of the RhoA pathway. Considering clinical and social support for medicinal cannabinoids in cancer treatment, our current and previous studies mechanistically demonstrate cannabinoid applications and efficiency of using agonists instead of antagonists which currently result in severe immune dysfunction due to the inhibition of CXCR4. This heterodimer can be used as a target for metastasis prevention due to CXCR4 in metastasis and cannabinoids in cancer metastasis treatment and pain management. Citation Format: Kisha Scarlett, Elshaddai White, Christopher Coke, Jada Carter, LaToya Bryant, Cimona V. Hinton. Agonist-induced heterodimerization between CXCR4 and CB2 inhibits Gα13/RhoA-mediated cell migration [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2512.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.